DURECT (DRRX) Earns Coverage Optimism Score of 0.10

Media coverage about DURECT (NASDAQ:DRRX) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DURECT earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 47.3364437767867 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Several analysts recently commented on DRRX shares. Laidlaw lowered their target price on DURECT from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Friday, October 20th. ValuEngine cut DURECT from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 21st. Stifel Nicolaus cut DURECT from a “buy” rating to a “hold” rating in a research report on Friday, October 20th. Finally, HC Wainwright restated a “hold” rating on shares of DURECT in a research report on Thursday, November 2nd.

DURECT (NASDAQ DRRX) traded up $0.01 on Thursday, reaching $1.16. The company had a trading volume of 452,800 shares, compared to its average volume of 1,199,555. DURECT has a 12-month low of $0.74 and a 12-month high of $2.17. The company has a current ratio of 1.67, a quick ratio of 1.57 and a debt-to-equity ratio of 1.46. The firm has a market cap of $174.04, a PE ratio of -7.73 and a beta of 1.68.

DURECT (NASDAQ:DRRX) last posted its earnings results on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.09. DURECT had a negative return on equity of 419.65% and a negative net margin of 62.57%. The firm had revenue of $20.75 million for the quarter, compared to analysts’ expectations of $5.09 million. equities analysts predict that DURECT will post -0.14 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3144482/durect-drrx-earns-coverage-optimism-score-of-0-10.html.

About DURECT

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Insider Buying and Selling by Quarter for DURECT (NASDAQ:DRRX)

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.